Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -18.26% | 24.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.26% | 24.79% | |||
| Cost of Revenue | 7.49% | -8.06% | |||
| Gross Profit | -8.44% | 8.95% | |||
| SG&A Expenses | 7.04% | -20.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.32% | -13.20% | |||
| Operating Income | -7.90% | 13.79% | |||
| Income Before Tax | -29.85% | -286.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.85% | -286.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.85% | -286.92% | |||
| EBIT | -7.90% | 13.79% | |||
| EBITDA | -9.24% | 14.04% | |||
| EPS Basic | -25.07% | -277.38% | |||
| Normalized Basic EPS | -15.53% | 17.16% | |||
| EPS Diluted | -25.19% | -277.38% | |||
| Normalized Diluted EPS | -15.53% | 17.04% | |||
| Average Basic Shares Outstanding | 3.82% | 5.38% | |||
| Average Diluted Shares Outstanding | 3.82% | 5.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||